Drug Search Results
More Filters [+]

VI-0521

Alternative Names: vi-0521, vi0521, vi 0521
Latest Update: 2024-06-18
Latest Update Note: Clinical Trial Update

Product Description

Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity.Ê (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369742/)

Mechanisms of Action: ADR Agonist,GABA Binder

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: VIVUS
Company Location: CAMPBELL CA 95008
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for VI-0521

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Pediatric Obesity|Overweight|Obesity

Phase 3: Obesity|Type 2 Diabetes

Phase 2: Sleep Apnea, Obstructive|Type 2 Diabetes|Glucose Metabolism Disorders|Overweight|Obesity

Phase 1: Healthy Volunteers|Torsades de Pointes|Obesity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OB-409

P4

Completed

Overweight

2023-04-11

OB-403

P4

Completed

Pediatric Obesity|Overweight

2021-04-16

OB-402

P4

Completed

Pediatric Obesity

2016-10-01

OB-404

P4

Completed

Overweight|Obesity

2014-11-01

Recent News Events

Date

Type

Title